Palisade Bio Announces Topline Results from U.S. Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions
09 août 2023 08h05 HE
|
Palisade Bio, Inc.
– Study did not achieve primary efficacy endpoint of reducing adhesions in LB1148 treated patients compared to placebo treated patients post bowel resection surgery Carlsbad, CA, Aug. 09, 2023 ...
Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study
05 juil. 2023 08h45 HE
|
Palisade Bio, Inc.
Topline data expected in Q3 2023 Carlsbad, CA, July 05, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute...
Palisade Bio Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
14 juin 2023 08h45 HE
|
Palisade Bio, Inc.
Live webcast fireside chat on Thursday, June 22nd at 11:30 AM ET Carlsbad, CA, June 14, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a biopharmaceutical company advancing therapies...
Palisade Bio’s LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts
24 mai 2023 08h45 HE
|
Palisade Bio, Inc.
Company approaching Phase 2 topline data readout for prevention of post-surgical abdominal adhesions Continued momentum with execution of ongoing dose optimization study with 25% enrollment...
Palisade Bio Reports First Quarter 2023 Financial Results
12 mai 2023 08h05 HE
|
Palisade Bio, Inc.
Company has sufficient cash expected to fund operations through 2024 Carlsbad, CA, May 12, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a...
Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study
11 mai 2023 09h05 HE
|
Palisade Bio, Inc.
Study designed to determine if a different dosing protocol for all indications might enhance the risk profile of LB1148 while simultaneously providing efficacy Company expects enrollment to be...
Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148
06 avr. 2023 09h00 HE
|
Palisade Bio, Inc.
Carlsbad, CA, April 06, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148
05 avr. 2023 08h35 HE
|
Palisade Bio, Inc.
Enrollment triggers milestone payment Carlsbad, CA and Shanghai, China, April 05, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a...
Palisade Bio Announces $6 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules
03 avr. 2023 08h30 HE
|
Palisade Bio, Inc.
Carlsbad, CA, April 03, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is...
Palisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update
23 mars 2023 08h05 HE
|
Palisade Bio, Inc.
Phase 2 topline data readout for prevention of post-surgical abdominal adhesions on track for Q2 2023 Strong balance sheet with sufficient cash expected to fund operations into mid-2024 ...